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The Use of Directing Groups Enables the Selective and Efficient 
Biocatalytic Oxidation of Unactivated Adamantyl CH Bonds 
Md Raihan Sarkar, Emma A. Hall, Samrat Dasgupta and Stephen G. Bell*[a] 
 
Abstract: Adamantane, 1- and 2-adamantanol and 2-adamantanone, 
were poor substrates for the cytochrome P450 enzyme CYP101B1. 
The CYP101B1 catalysed oxidation of 1-adamantyl methyl ketone, 
and methyl 2-(1-adamantyl acetate), were more active generating a 
majority of the 4-hydroxy metabolite. Substrate engineering using 
acetate and isobutyrate ester directing groups significantly increased 
the affinity, activity and coupling efficiency of CYP101B1 for the esters 
compared to the parent adamantanols, resulting in enhanced product 
formation rates (720 to 1350 nmol.(nmol-P450)–1.min–1). The majority 
of the turnovers were selective for CH bond hydroxylation with 4-
hydroxy-1-adamantyl isobutyrate and the 5-hydroxy-2-adamantyl 
esters being generated as the sole majority product, 97%, with high 
total turnover numbers, ranging from 4130 to 16500. In addition N-(1-
adamantyl)acetamide, was oxidised by CYP101B1 whereas 1-
adamantylamine, was not. Whole-cell biocatalytic reactions were 
used to generate the products in good yield. Overall the use of ester 
protecting groups and the modification of the amine to an amide 
enabled the more efficient and selective biocatalytic oxidation of 
adamantane frameworks. 
Introduction 
The application of cytochrome P450 (CYP) enzymes as 
biocatalysts for the regio- and stereo-selective insertion of an 
oxygen atom into the chemically inert carbon-hydrogen bonds of 
saturated hydrocarbons is of great interest due to the difficulties 
associated with these reactions.[1] Many monooxygenase 
enzymes have been investigated as potential biocatalysts for the 
oxidation of organic molecules with those from bacteria and fungi 
being the most promising.[2] The monooxygenase activity of CYP 
enzymes requires two electrons that are usually derived from 
NAD(P)H and these are delivered one at a time, when needed, to 
the CYP enzymes by electron transfer proteins.[3] The 
identification and application of highly active systems with known 
electron transfer partners coupled with a well-defined substrate 
range greatly facilitates biocatalytic CH bond oxidation of organic 
molecules.[4] For example CYP102A1, from Bacillus megaterium, 
which is highly active for fatty acid substrates, has been modified 
via protein engineering to facilitate the selective oxidation of 
aliphatic and aromatic CH bonds in many other substrates.[1e, 4b, 
4c, 5] Class I CYP enzymes, such as CYP101A1 (P450cam), from 
a Pseudomonas sp., whose electron transfer systems consist of 
a flavin-dependent ferredoxin reductase and a ferredoxin, are 
also capable of high monooxygenase activities and the selective 
oxidation of hydrocarbons.[4f, 6] The wild-type enzymes and mutant 
forms of various class I CYPs have been reported to be 
biocatalysts for the oxidation of gaseous alkanes, hydrocarbons, 
terpenes and alkylbenzenes.[4a, 6b, 7] 
Novosphingobium species are able to degrade a variety of 
hydrocarbons and therefore the oxygenase enzymes from this 
bacterium have potential applications as biocatalysts.[8] The 
bacterium Novosphingobium aromaticivorans DSM12444 
contains many monooxygenase and dioxygenase enzyme coding 
genes.[8a] These include the P450 enzymes CYP101B1, 
CYP101C1, CYP101D1 and CYP101D2, which are related to 
CYP101A1. The CYP101 family of P450 enzymes are able to bind 
norisoprenoids, camphor and certain terpenoids with high 
affinity.[4f, 9] A class I electron transfer system from N. 
aromaticivorans, consisting of a flavin-dependent ferredoxin 
reductase, ArR, and a [2Fe-2S] ferredoxin, Arx, has been used to 
support the activity the CYP101B1, C1, D1 and D2 enzymes.[2c, 4f, 
9a-c] Whole-cell systems containing these CYP enzymes coupled 
to, ArR and Arx, are capable of product formation on the gram-
per-litre scale in shake flasks.[9a] CYP101B1 is a highly efficient 
biocatalyst for the CH bond oxidation of norisoprenoids and 
monoterpenoid acetates.[9c, 10] The acetate side chain of the esters 
resembles the butenone side chain of norisoprenoids allowing 
substrate binding with high affinity which holds the substrate in 
place for efficient and selective oxidation. These oxidation 
reactions proceed with high catalytic activity, turnover number 
and coupling efficiency.[10] Therefore ester protecting groups, 
such as acetate which are simple to add to and remove from 
alcohols, and the amide equivalents of amines could act as 
chemical auxiliaries and directing groups to enable the improved 
oxidation of low affinity substrates as described by Griengl and 
others.[11] 
Substituted tricyclic adamantane compounds are important 
chemicals which are used in the production of functional materials, 
polymers and pharmaceuticals.[12] Current chemical methods 
require harsh oxidants, are poorly selective and are prone to 
overoxidation.[12] A number of microbial strains are capable of 
slowly oxidising adamantane, 1, and its derivatives and several 
CYP enzymes including CYP101A1 have been reported to 
hydroxylate adamantane and 2-adamantanone.[12-13] Here we 
investigate the biocatalytic oxidation of substrates with an 
adamantane skeleton by CYP101B1. We demonstrate that the 
enzyme is capable of acting as an efficient biocatalyst for the 
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oxidation of acetate, acetamide and isobutyrate protected 
adamantyl derivatives. 
Results  
The oxidation adamantane, 2-adamantanone and 
adamantanols by CYP101B1 
 
Tricyclic substrates, including adamantane, 1, 1- and 2-
adamantanol, 2 and 3, and 2-adamantanone, 4, were analysed 
with CYP101B1 (Fig. 1). The addition of 1-adamantanol, 2, and 2-
adamantanol, 3, induced significant type I spin state shifts with 
CYP101B1 (55-60%). 2-Adamantanone, 4, and adamantane, 1, 
engendering lower shifts (20-30%, Table 1, Fig. S1). However 1-
adamantanol, 2, bound with lower affinity to CYP101B1 than 2-
adamantanone, 4 (Table 1, Fig. S2). Low solubility and weak 
binding prevented the accurate measurement of the dissociation 
constants of 2-adamantanol, 3, and adamantane, 1.  
Figure 1. Substrates tested with CYP101B1 in this study. 
The product formation rate and the coupling efficiency, 
which is a measure of the productive use of the NADH reducing 
equivalents, arising from the CYP101B1 catalysed turnover of 
adamantane, 1, and the adamantanols, 2 and 3, were paltry 
resulting in low levels of metabolite formation (Table 2). The 
product formation activity of 2-adamantanone, 4, with CYP101B1 
was the highest (PFR 103 nmol.(nmol-P450)–1.min–1; henceforth 
abbreviated to min1) being tenfold more active than the next best 
tricyclic compound (1-adamantanol, 2). By way of comparison, 
the activity of CYP101B1 with 2-adamantanone was half that of 
the monoterpenoids, (1R)-(+)-camphor, 1,8-cineole and (+)-
fenchone and ten-fold lower than those of norisoprenoids and 
monoterpenoid acetates.[14]  
 
Table 1. Substrate binding, kinetic and coupling data for CYP101B1 with 
adamantane and related substrates. Steady state turnover activities were 
measured using a ArR:Arx:CYP101B1 concentration ratio of 1:10:1 (0.5 μM 










1 30% -[g] 140 ± 10 0.2 ± 0.1 0.11 n.d. 
2 60% 711 ± 26 415 ± 55 11 ± 4 3 n.d. 
3 55% -[g] 563 ± 10 11 ± 3 2 n.d. 
4 35% 548 ± 15 669 ± 7 104 ± 9 16 n.d. 
5 70% 32 ± 1.0 923 ± 31 473 ± 22 51 6690 
6 95% 0.2 ± 0.03 1120 ± 4 704 ± 28 63 16500 
7 90% 3.9 ±0.1 1300 ± 16 821 ± 27 63 6050 
8 95% 1.6 ± 0.1 1360 ± 7 1350 ± 22 99 4130 
9 90% 1.9 ± 0.1 1170 ± 11 877 ± 18 75 11500 
10 90% 0.6 ± 0.04 1060 ± 6 722 ± 10 68 7090 
11 <5% -[g] 35 ± 0.3 n.p. n.p n.p. 
12 50% 55 ± 5 955 ± 25 166 ± 9 17 780 
[a] HS: the percentage of high spin state heme iron induced by substrate 
binding. [b] Kd: the dissociation constant, μM [c] N: NADH turnover rate. [d] 
PFR: product formation rate. The rates are reported as mean  S.D. (n  3) 
and given in nmol.(nmol-P450)–1.min–1. [e] C: Coupling efficiency, which is 
the percentage of NADH consumed in the reaction that led to the formation 
of products. [f] TTN: The total turnover numbers (TTN) were determined 
using assays set up with the same ratio of enzymes as those above but with 
0.1 μM CYP enzyme, 2 mM substrate and 4 mM NADH (theoretical 
maximum value 20,000). [g] Not calculated due to low detector response to 
addition of substrate or low substrate solubility interfered with the titration. 
n.p. no detectable product. n.d. not determined. 
 
Adamantane, 1, was oxidised by CYP101B1 to form 
predominantly 1-adamantanol, 2 (90%) with 2-adamantanol, 3, 
being observed as a side product (10%, Scheme 1). Due to the 
low levels of product formation these were identified via GC-
coelution experiments with authentic chemical standards.  
CYP101B1 oxidation of 2-adamantanone, 4, generated two 
products (both m/z = 166.1, Fig. S3(a)) and these were 
synthesised using a whole-cell oxidation system.[9a] After 
separation by silica gel chromatography the hydroxylated 
metabolites were identified by their mass fragmentation pattern 
and NMR spectra as 5-hydroxy-2-adamantanone, 4a (45%) and 
6-hydroxy-2-adamantanone, 4b (55%, Scheme 1, Fig. S3(a), Fig. 
S4, Fig. S5(a), Fig. S5(b)).[13b]  






Scheme 1. The major products formed from CYP101B1 turnovers of 
adamantane, adamantanols and 2-adamantanone. No product was formed with 
1-adamantylamine. 
The oxidation of 2-adamantanol, 3, was more complicated 
generating multiple products and the assessment of the product 
distribution was hampered by overlapping retention times. Whole-
cell oxidation of 2-adamantanol produced six metabolites, two of 
which were identified as 6-hydroxy-2-adamantanone, 4a, and 5-
hydroxy-2-adamantanone, 4b, by coelution with the products from 
the turnovers of 2-adamantanone, 4, and their MS fragmentation 
patterns (m/z = 166.1, Fig. S4). 1,4-Adamantanediol, 2b, was also 
identified after isolation and characterisation by NMR and MS (Fig. 
S4 and experimental section in supporting information). Another 
product was tentatively assigned as 2,6-adamantanediol, 3a, 
based on its MS analysis and the subsequent formation of the 
further oxidation product 6-hydroxy-2-adamantanone, 4a 
(Scheme 1, Fig. S3(a), Fig. S4). We also observed the formation 
of a small amount of a metabolite which had an MS fragmentation 
pattern characteristic of 1,2-adamantanediol, 3c (Fig. S4).[15] By 
lengthening the duration of the whole-cell turnovers we observed 
the formation of 2,6-adamantandione, 3d (m/z = 164.1, Fig. S4).  
Oxidation of 1-adamantanol, 2, generated a major product 
which was assigned as 1,3-adamantanediol, 2a, from its mass 
spectrum (Scheme 1, Fig. S3(a), Fig. S4).[13c] An additional minor 
product which coeluted with 1,4-adamantendiol, 2b, was also 
detected. The low levels of product formation prevented further 
more detailed characterisation.  
 
The oxidation adamantane ketone, ester, amine and amide 
derivatives by CYP101B1 
 
CYP101B1 binds norisoprenoid substrates which contain a 
butenone side chain with high affinity. The ketone moiety in these 
molecules has been shown to be important for tight binding.[10] In 
order to investigate if appending a ketone containing side chain 
to the tricyclic adamantane skeleton would improve substrate 
binding to CYP101B1 we tested 1-adamantyl methyl ketone, 5, 
(Fig. 1). Addition of this substrate to CYP101B1 induced a shift in 
the spin-state to the high-spin form of 70%. While this was only 
slightly superior to the shift induced by 1-adamantanol, 2, the 
binding affinity was an order of magnitude higher (Kd = 32 ± 1.0 
µM, Table 1, Fig. S2). The NADH oxidation activity and the 
product formation rate of 473 ± 22 min1 were also greater than 
that of 2-adamantanone, 4. The 4-fold increase in the activity 
predominantly arose due to an improvement in the coupling 
efficiency from 16% to 51% (Table 1). Two products, in an 
approximate 3:1 ratio, were detected in the GC-MS analysis of the 
turnovers (Fig. S3(b)). These were both identified as 
monohydroxylated monooxygenase products from their MS data 
(m/z = 194.05, Fig. S4). The whole-cell oxidation system was 
used to generate both products in more substantial quantities and 
these were extracted and separated by silica chromatography 
(Fig. S3(b)). NMR spectroscopy was used to identify the major 
and minor products as trans-4-hydroxy-1-adamantyl methyl 
ketone, 5a, and 3-hydroxy-1-adamantyl methyl ketone, 5b, 
respectively (Scheme 2, Fig. S5(c), Fig. S5(d)). 
Given the improvement observed in the binding affinity and 
activity of 1-adamantyl methyl ketone, 5, over 2-adamantanone, 
4, and as monoterpenoid acetates have been reported to have a 
high binding affinity to CYP101B1 we tested adamantyl 
substrates which contain ester groups.[10] Methyl 2-(1-adamantyl 
acetate) 6, induced an almost complete shift of CYP101B1 to the 
high spin form and bound with thirty-fold higher affinity than 1-
adamantyl methyl ketone, 5 (Table 1, Fig. S1, Fig. S2). The NADH 
oxidation activity and coupling efficiency of the turnovers were 
also high (Table 1) resulting in a product formation rate of 704 ± 
28 min–1. The turnover was also more selective than that of 1-
adamantyl methyl ketone, 5, generating two products in the ratio 
84:16 (Fig. S3(c)). Both had masses consistent with them being 
alcohols (m/z = 224.05, Fig. S4). After isolation the major product 
was identified using NMR as methyl 2-(trans-4-hydroxy-1-
adamantyl) acetate, 6a (Fig. S5(e)). The minor product was 
characterised as methyl 2-(3-hydroxy-1-adamantyl) acetate, 6b 
(Scheme 2, Fig. S5(f)). 
 
 






Scheme 2. The products formed from CYP101B1 turnovers of adamantane 
ester and ketone analogues. * there is a small, ≤ 3%, amount of an 
uncharacterised minor metabolite with a MS consistent with a hydroxylation 
product detected in these turnovers. 
We next assessed if substrate engineering of 1- and 2-
adamantanol, 2 and 3, using an ester protecting group could 
improve the binding affinity and therefore the turnover activity. 
The acetate and isobutyrate esters of both adamantanols were 
synthesised, 7-10, characterised and tested as substrates for 
CYP101B1 (see experimental section in supporting information, 
Fig. 1, Fig. S6).  
Addition of both 1-adamantyl acetate, 7, and 1-adamantyl 
isobutyrate, 8, induced an almost complete shift of CYP101B1 to 
the high spin form (90%, Fig. S1). The affinity of CYP101B1 for 
both was high with that of the isobutyrate ester, 1.6 M exceeding 
that of the acetate equivalent, 3.9 M (Table 1, Fig. S2). The 
NADH oxidation rates of both were comparable, 1300 and 1360 
min–1, but the coupling efficiency of 1-adamantyl isobutyrate, 8, 
was greater, 99%, than 1-adamantyl acetate, 7, 63%. This 
resulted in a higher product formation activity for the isobutyrate 
ester, 1350 min–1 than for the acetate, 821 min–1 (Table 1).  
 
Figure 2 (a) The GC-MS analysis of the whole-cell turnover of 1-adamantyl 
acetate, 7, by CYP101B1 analysed after 3 hours; 1-adamantyl acetate, 7 (RT 
6.8 min) and the products; 3-hydroxy-1-adamantyl acetate, 7b (RT 8.9 min) and 
trans-4-hydroxy-1-adamantyl acetate, 7a (RT 9.9 min). (b) The GC-MS analysis 
of the in vitro turnover of 1-adamantyl isobutyrate, 8, by CYP101B1; 1-
adamantyl isobutyrate, 8 (RT 8.6 min) and the product; trans-4-hydroxy-1-
adamantyl isobutyrate, 8a (RT 11.5 min). The minor peak (3%) at 10.6 min has 
a MS and retention time consistent with it being 3-hydroxy-1-adamantyl 
isobutyrate, 8b. Impurities are labelled (*), in figure 2 (a) the peak to the left of 
the substrate results is from 1-adamantanol from hydrolysis of the ester 
substrate (not present in other turnovers; Fig. S3d). 







The turnover of 1-adamantyl acetate, 7, generated two 
hydroxylated products (m/z = 210.0, Fig. S4) in an approximate 
4:1 ratio (Scheme 2, Fig. 2(a), Fig.S3(d)). The major product was 
isolated and identified using NMR as trans-4-hydroxy-1-
adamantyl acetate, 7a (Fig. S5(g)). The minor product was not 
isolated as a pure compound but had NMR spectra consistent 
with 3-hydroxy-1-adamantyl acetate, 7b (Scheme 2). CYP101B1 
catalysed oxidation of 1-adamantyl isobutyrate, 8, generated one 
major hydroxylated product, 97% (m/z = 238.05, Fig. 2(b), Fig. 
S3(e), Fig. S4) which was purified and characterised as trans-4-
hydroxy-1-adamantyl isobutyrate, 8a (Scheme 2, Fig.S5(h)). A 
small peak was detected via GC-MS which had a mass spectrum 
and retention time consistent with that of 3-hydroxy-1-adamantyl 
isobutyrate but was not isolated in sufficient yield from the whole-
cell turnovers to be fully characterised (Fig. 2(b)). 
 
Figure 3. (a) The GC-MS analysis of the in vitro turnover of 2-adamantyl acetate, 
9, by CYP101B1; 2-adamantyl acetate, 9 (RT 7.1 min) and the product; 5-
hydroxy-2-adamantyl acetate, 9a (RT 9.4 min). (b) The GC-MS analysis of the 
in vitro turnover of 2-adamantyl isobutyrate, 10, by CYP101B1; 2-adamantyl 
isobutyrate, 10 (RT 8.9 min) and the product; 5-hydroxy-2-adamantyl 
isobutyrate, 10a (RT 11.1 min). Impurities are labelled (*). Both turnovers 
contained a minor product (9b and 10b) at a higher retention time with an MS 
consistent with a hydroxylation product. 
The addition of both 2-adamantyl acetate, 9, and 2-
adamantyl isobutyrate, 10, to CYP101B1 induced a spin state of 
90% high-spin (Fig. 1, Fig. S1). In line with the large spin state 
shift both substrates bound to the enzyme with high affinity. The 
dissociation constants were tighter than their 1-adamantyl ester 
counterparts (1.9 M and 0.6 M, Table 1, Fig. S2). The NADH 
oxidation rates and coupling efficiencies of both adamantyl esters 
were high (Table 1). The coupling efficiency of the turnover of 2-
adamantyl acetate, 9, was greater resulting in a product formation 
rate of 877 min–1 which was similar to that of 1-adamantyl acetate, 
7 (Table 1). 
GC and GC-MS analysis of the turnovers of both of these 
substrates showed the presence of a single major, hydroxylated 
product, ≥97 % (m/z = 210.1 and 238.15, respectively, Fig. 3, Fig. 
S3(f), S3(g), Fig. S4). After whole-cell oxidations and purification 
the products were established as 5-hydroxy-2-adamantyl acetate, 
9a (Scheme 2, Fig. S5(i)) and 5-hydroxy-2-adamantyl isobutyrate, 
10a, using their NMR spectra (Fig. S5(j)). The lower coupling and 
NADH oxidation rate of CYP101B1 with 2-adamantyl isobutyrate, 
10, resulted in a product formation rate of 722 min–1 (Table 1). 
The minor product in each turnover, <3%, was observed at a 
higher retention time and had mass spectra consistent with a 
hydroxylation product but these could not be characterised further. 
Finally we tested the nitrogen containing compounds 1-
adamantylamine, 11 (amantadine) and N-(1-
adamantyl)acetamide, 12, with CYP101B1 (Fig. 1). 1-
Adamantylamine, 11, did not induce any significant shift in the 
spin state of CYP101B1 enzyme (Fig. S1). The NADH oxidation 
activity was low and no product formation was detected (Table 1, 
Scheme 1, Fig. S3(i)). Converting the amine to the acetamide 
resulted in a significant increase in the spin state of CYP101B1 
upon substrate binding (50%, Table 1). However, the binding 
affinity, as measured by the dissociation constant, was lower than 
those of the ester derivatives and 1-adamantyl methyl ketone, 5 
(Table 1). The rate of NADH oxidation in the CYP101B1 system 
brought about by N-(1-adamantyl)acetamide, 12, was high but the 
product formation activity was moderate, 166 min1, due to lower 
coupling efficiency of the reducing equivalents to metabolite 
formation (Table 1).  
Two hydroxylated products (m/z = 209.1) were identified by 
GC-MS analysis in an approximate 3:1 ratio (Scheme 2, Fig. 4, 
Fig. S3). These were generated in greater quantities via a whole-
cell oxidation system. The two products were isolated in a pure 
form after extraction and silica gel chromatography (the products 
are highly soluble in aqueous solution).[16] These were identified 
as 4-hydroxy-N-(1-adamantyl)acetamide, 12a, and 3-hydroxy-N-
(1-adamantyl)acetamide, 12b, using their NMR spectra (Scheme 
2, Fig. S5(k), Fig. S5(l)). Due to overlapping peaks we were 
unable to definitively assign the stereochemistry of the 4-hydroxy 
product (Fig. S5(k)). 







Figure 4. The GC-MS analysis of the whole-cell turnover of N-(1-
adamantyl)acetamide, 12, by CYP101B1. The substrate N-(1-
adamantyl)acetamide, 12 (RT 9.75 min) and the products; 3-hydroxy-N-(1-
adamantyl)acetatamide, 12b (RT 11.8 min) and 4-hydroxy-N-(1-
adamantyl)acetamide, 12a (RT 12.8 min). 
The turnover data (PFR and coupling efficiency) indicate 
that CYP101B1 is a good biocatalyst for synthetic applications 
with these adamantane ketone, ester and amide derivatives 
(Table 1). The standard in vitro turnover assays have turnover 
numbers limited by the amount of NADH added, which is lower 
than the substrate concentration. Therefore in order to measure 
the efficiency of the enzyme over a longer period of time we 
measured the total turnover number (TTN) with the best 
substrates using lower concentrations of the enzyme and an 
excess of reducing equivalents. In vitro the TTN of CYP101B1 
with the esters and ketones, 5 to 10, were high, ranging from 4130 
to 16500 (Table 1). These were comparable to those obtained 
with norisoprenoids and monoterpenoid acetates (5240-8660) 
and show that the CYP101B1 enzyme is not rapidly deactivated 
by these substrates.[10] The TTN of the isobutyrate esters, 8 and 
10, were lower than those of the acetate esters, 7 and 9 (Table 1). 
The highest TTN was observed with methyl 2-(1-adamantyl 
acetate) 6. The TTN of the N-(1-adamantyl)acetamide, 12, was 
lower in line with the lower coupling efficiency observed with this 
substrate and would require further optimisation (Table 1). 
The products generated using low cell density, shake flask. 
whole-cell oxidations (200 mL scale) were the same as those from 
the in vitro turnovers, Fig. 2-4, Fig. S3). The product yields and 
conversions from these oxidation reactions using low cell density 
cultures were also high. Despite the lower in vitro product 
formation rates and coupling efficiency of N-(1-
adamantyl)acetamide, 12, all of the added substrate (3 mM, 135 
mg in 200 mL) was converted after 20 hours in the whole-cell 
turnovers. For the ester and ketone compounds the conversion of 
the substrate into product ranged from 40 – 80% of the added 
substrate (3-4 mM in 200 mL) in the shake flask reactions which 
corresponds to an excess of 4000 turnovers (based on a P450 
concentration of 0.33 µM in the cell growths for the whole-cell 
turnovers).[9a] The yield of total purified products after silica 
chromatography ranged from 85 to 255 mg per litre for the esters 
and ketones. The conversions and yields could be significantly 
improved using higher density cell cultures in a fermentor with 
more control of the pH, nutrients combined with a substrate 
feeding/product removal regime. 
Discussion  
CYP101B1 is able to oxidise a broad range of substrates and 
optimal catalytic efficiency is achieved for norisoprenoids, 
monoterpenoid acetates and now adamantyl esters. All of these 
have a carbonyl group on a side chain attached to substituted ring 
systems. These substrates are hydroxylated with high activity, 
total turnover numbers and regioselectivity. The oxidation of 
adamantane derivatives is of great interest as they are building 
blocks for more complex drug molecules and polymers. Microbial 
oxidative biotransformations of adamantane, 1, 2-adamantanone, 
4, adamantanols, 2 and 3, and related substrates including the 
acetate esters are possible using different bacteria, including 
Streptomyces, and fungi including Basidiomycota, Absidia 
cylindrospora and Beauveria (Sporotrichum) sulfurescens.[12, 13c] 
16-17] Certain P450 enzymes and their mutants have also been 
reported to oxidise adamantane based substrates including 
CYP101A1 and CYP101D2 though at lower activities than the 
turnover of the esters reported here.[13a, 13b, 13d] 
The importance of the ketone containing side chain for 
efficient biocatalysis with CYP101B1 can be clearly seen by 
comparing the binding properties and activities of the 
adamantanols, 2 and 3, and 2-adamantanone, 4, with the 
adamantyl acetates and isobutyrates, 7-10. The turnovers of 2-
adamantanone, 4, and 2-adamantanol, 3, resulted in the 
formation of low levels of multiple products. Oxidation of 
adamantane, 1, and 1-adamantanol, 2, were selective but the 
activities were low. The oxidation of the esters proceeded more 
efficiently and was more selective. Modification of the ester 
substituent was also observed to have an effect on the binding 
and catalytic properties. For example methyl 2-(1-adamantyl 
acetate), 6, bound with the highest affinity to CYP101B1 and the 
isobutyrate esters, 8 and 10, bound more tightly than the 
equivalent acetates, 7 and 9. The oxidation of 1-adamantyl 
isobutyrate, 8, was also selective for the formation of the trans-4-
hydroxy product, 8a, whereas other substituents at the equivalent 
positions led to the production of the 3-hydroxy metabolite as a 
significant minor product (16  28%). It is of note that the 
selectivity of the isobutyrate ester, 8, was higher than that of the 
acetate ester, 7. Furthermore the selectivity of ester oxidation has 
been altered compared to 1-adamantanol, 2, oxidation by 
CYP101B1 which favoured oxidation to 1,3-adamantanediol, 2a. 
Therefore presence and the size of the ester group must affect 
the orientation of the substrate in the enzyme active site. The 
lower TTN of the isobutyrate esters despite the higher product 
formation activity may be in part due to lower solubility and 
requires further optimisation. 
For the 2-adamantyl acetate and isobutyrate substrates, 9 
and 10, bond abstraction occurs predominantly at the more 






reactive bridgehead position to produce the 5-hydroxy metabolite. 
For 2-adamantanone, 4, and 2-adamantanol, 3, significant levels 
of oxidation were also observed at the methylene groups at C6. 
Overall the ketone containing side chain appeared to hold the 
adamantyl tricyclic ring in such a position that only certain CH 
bonds are attacked compared to the parent adamantanols which 
presumably bind in multiple orientations or are mobile in the 
enzyme active site. For the adamantyl substrates with ester and 
amide substituents at the bridgehead carbon (5-8 and 12) 
oxidation to the trans-4-hydroxy was always favoured over the 
more reactive tertiary position. In addition no product 
corresponding to a cis-4-hydroxy species was detected in any of 
the substrate turnovers.  
1-Adamantylamine, 11, and its derivatives e.g. rimantadine 
and adapromine are drug molecules which are used as anti-
virals.[18] The N-(1-adamantyl)acetamide, 12, framework is also 
found in many drugs. e.g. tromantadine.[19] The selective 
functionalisation of the acetamide derivative could generate drug 
metabolites for activity studies or could be used to selectively add 
functional groups for the development of new drugs with improved 
properties. The lower coupling efficiency and therefore product 
formation activity and total turnover numbers of the acetamide 
versus the ester requires further investigation but could be due an 
alternative binding mode as reflected in the lower spin state shift 
induced by the acetamide. Despite the lower turnover activity the 
substrate was efficiently converted using the whole-cell oxidation 
system and the reduced isolated yield of product could be 
improved using a different extraction method for the more water 
soluble products.[16] 
The selective oxidation of the adamantyl esters with such 
high activity by CYP101B1 would be useful for synthetic chemistry. 
Acetate, acetamide, isobutyrate and other ester or amide groups 
could be used as directing groups to improve activity and tune the 
selectivity without protein engineering. The crystal structure of 
CYP101B1 has not yet been solved but using ester and amide 
groups we have been able to improve the activity and selectivity 
of oxidation with a range of adamantyl substrates. The in vitro 
activity and total turnovers achieved with CYP101B1 are 
significantly greater than those reported for the majority of other 
P450 systems. Large quantities of the products were generated 
(up to 3 mM conversion of all of the added substrate, 680 mg 
L1) using the whole-cell E. coli oxidation system at low cell 
densities in shake flask without optimisation. This is encouraging 
for the scale-up of enzyme activity in the future. 
Conclusions 
CYP101B1 is able to efficiently oxidise adamantane derivatives 
including adamantyl acetates and isobutyrates, 7-10, 1-
adamantyl methyl ketone, 5, and methyl 2-(1-adamantyl acetate) 
6. It was also able to oxidise N-(1-adamantyl)acetamide, 12, 
whose structural framework is a compnonent of a class of drug 
molecules. The oxidation of adamantane, 1, 2-adamantanone, 4 
and adamantanols, 2 and 3, was less efficient and was 
unselective and 1-adamantylamine, 11, was not a substrate for 
the enzyme. The modification of alcohols and amines by the 
addition of an ester or amide directing group was a simple method 
for improving the activity and selectivity of the oxidations. 
Modification of the size of the ester resulted in increased binding 
affinity and improved the selectivity. As a result we were able to 
selectively oxidise unactivated CH bonds at product formation 
rates of up to 1360 min1 and coupling efficiencies approaching 
99%. The isobutyrate ester of both adamantanols resulted in 
increased binding affinity compared to the acetate. In the case of 
1-adamantyl isobutyrate, 8, this resulted in increased activity, 
coupling efficiency and selectivity. When incorporated into a 
whole-cell oxidation system, with the physiological electron 
transfer partners, ArR and Arx, CYP101B1 was capable of 
generating the oxidation products in higher yields. The efficient 
and selective turnovers catalysed by CYP101B1 will enable the 
development of biocatalytic routes to functionalise adamantane 
and other hydrocarbon derivatives. 
 
Supporting information summary paragraph 
The Experimental Section, NMR data and spectra, substrate 
binding analysis, GC-MS and GC chromatograms and mass 
spectra are available in the Supporting Information. 
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The selective biocatalytic oxidation 
of the unactivated CH bonds in 
adamantanols and an amine 
analogue was achieved by 
modification of the substrate using 
ester and amide directing groups. 
This approach improved the binding 
affinity, activity and selectivity of 
product formation enabling the 
efficient generation of the 
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